The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).
B. M. Wolpin
Research Funding - Agensys
E. M. O'Reilly
Research Funding - Agensys
Y. Ko
Research Funding - Agensys
L. S. Blaszkowsky
Research Funding - Agensys
M. U. Rarick
Research Funding - Agensys
C. M. S. Rocha Lima
Research Funding - Agensys
P. S. Ritch
Research Funding - Agensys
E. Chan
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genentech; ImClone Systems; Pfizer; Sanofi
Research Funding - Agensys; Amgen; Bristol-Myers Squibb; Genentech; Idera Pharmaceuticals; Lilly; Merck; MethylGene; Pfizer
J. L. Spratlin
Research Funding - Agensys
T. Macarulla
Research Funding - Agensys
E. McWhirter
Research Funding - Agensys
D. Pezet
Research Funding - Agensys
M. Lichinitser
Research Funding - Agensys
L. D. Roman
Research Funding - Agensys
A. Hartford
Employment or Leadership Position - Agensys
L. Jackson
Employment or Leadership Position - Agensys
M. Vincent
Employment or Leadership Position - Agensys
L. M. Reyno
Employment or Leadership Position - Agensys
M. Hidalgo
Research Funding - Agensys